Crossmark

Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease

Crossref DOI link: https://doi.org/10.1007/s40121-021-00573-w

Published Online: 2021-12-07

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Scholz, Stefan

Schwarz, Magdalena http://orcid.org/0000-0002-4850-8597
Beck, Ekkehard

Meszaros, Kinga

Schneider, Melanie

Ultsch, Bernhard

Greiner, Wolfgang
Funding

Funding for this research was provided by:

GlaxoSmithKline Biologicals SA (HO-17-19109)
License Information

Text and Data Mining valid from 2021-12-07

Version of Record valid from 2021-12-07
More Information

Article History

Received: 18 October 2021

Accepted: 22 November 2021

First Online: 7 December 2021

Change Date: 13 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40121-022-00618-8

Updates are available Correction dated 2022-04-13

Click to view Correction: https://doi.org/10.1007/s40121-022-00618-8